ProCE Banner Activity

Expert Analysis: Insights for International Clinicians on New Data From HIV Glasgow 2020

Conference Coverage
Text Module

Experts review new study data from HIV Glasgow 2020 on current and emerging ART options as well as comorbidity management that will affect practice for international clinicians managing HIV patient care around the world.

Released: November 06, 2020

Expiration: November 05, 2021

No longer available for credit.

Share

Faculty

Marina Klein

Marina Klein, MD, MSc, FRCP(C)

Professor of Medicine
Division of Infectious Diseases and Chronic Viral Illness Service
McGill University Health Centre
McGill University
Montreal, Canada

Jean-Michel Molina

Jean-Michel Molina, MD, PhD

Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and lariboisière
Paris, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Educational grant provided by:

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Target Audience

This program is intended for physicians, pharmacists, and other healthcare providers who care for patients with HIV.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate data on HIV prevention strategies into care of patients with HIV or at risk of HIV
  • Devise management strategies based on the results of recent clinical studies of established ARV agents in patients with HIV
  • Critically evaluate data on investigational ART regimens that informs their anticipated role in clinical practice

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Marina Klein, MD, MSc, FRCP(C)

Professor of Medicine
Division of Infectious Diseases and Chronic Viral Illness Service
McGill University Health Centre
McGill University
Montreal, Canada

Marina Klein, MD, MSc, FRCP(C) has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, Merck, and ViiV Healthcare.

Jean-Michel Molina, MD, PhD

Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and lariboisière
Paris, France

Jean-Michel Molina, MD, PhD, has disclosed that he has received funds for research support from Gilead Sciences, and consulting fees from Aelix, Gilead Sciences, Merck, and ViiV Healthcare.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

 

Goal


The goal of this activity is to improve learners’ competence in translating the most clinically significant data from an important scientific meeting into practical management strategies for persons at risk of or infected with HIV.